Daily Medication Pearl: Symtuza (Darunavir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide)
May 25th 2022Symtuza, a 4-drug combination of darunavir (DRV), a HIV-1 protease inhibitor; cobicistat (COBI), a CYP3A inhibitor; and emtricitabine (FTC) and tenofovir alafenamide (TAF), both HIV-1 nucleoside analog reverse transcriptase inhibitors, is indicated as a complete regimen for the treatment of HIV-1 infection in patients who weigh at least 40 kg.
Read More
Daily Medication Pearl: Danyelza (Naxitamab-gqgk)
May 17th 2022Naxitamab-gqgk (Danyelza) is for the treatment of pediatric and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who have demonstrated a partial response, minor response, or stable disease to prior therapy.
Read More
Daily Medication Pearl: Obeticholic Acid (Ocaliva)
May 13th 2022Obeticholic acid (Ocaliva) is indicated for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as monotherapy in adults unable to tolerate UDCA.
Read More